EMA Supports Use of Tocilizumab in Severe COVID-19 Patients

The European Medicines Agency (EMA) on Monday authorized the use of tocilizumab, an arthritis treatment, for patients hospitalized for a serious form of COVID-19, claiming that it reduces the risk of death.

SIGHT: What does the Minsa vaccination card app have and what is missing?

The anti-inflammatory, manufactured by the Swiss pharmaceutical giant Roche and marketed under the name of RoActemra in Europe, should be administered with steroids to this category of patients, concluded the European Union regulator, thus ahead of the World Health Organization and States United.

The EMA has recommended expanding the use of tocilizumab to adults with COVID-19 who are receiving “systemic” steroid therapy and / or mechanical ventilation.

SIGHT: Omicron: How can scientists update coronavirus vaccines for the new variant?

The European Commission will now have to follow the recommendation of the regulator, based in Amsterdam, the Netherlands.

Formerly available for the treatment of arthritis in adults and children, an overreaction of the immune system to coronavirus.

SIGHT: Omicron: 5 Most Googled Questions About Variation (& Expert Answers)

According to the EMA, a study with more than 4,000 seriously ill patients with COVID-19 showed that the drug, administered intravenously or by injection, reduced the risk of death and the

However, it should be prescribed together with corticosteroids because “An increase in mortality cannot be excluded” if used without them, stressed.

The treatment adds to the EU’s range of tools to fight COVID-19. These already include four vaccines, two antibody treatments, including Roche’s Regeneron, and the future emergency use of the pill developed by Merck.

• Ómicron: what is epistasis and why is it the key to understanding how dangerous the new variant of the coronavirus is
• Omicron: 5 Most Googled Questions About Variation (& Expert Answers)
• Omicron | Does the new variant cause a more serious disease?
• What does the Minsa vaccination card app have and what is missing?
• EMA Supports the Use of RoActemra in Adults with Severe COVID-19
• “The first thing I thought is that it was covid”: what is it like to get dengue fever in an area plagued by constant outbreaks
• COVID-19 | Why is the booster dose still important despite the Omicron variant?
• “The next pandemic could be more contagious or deadly,” says vaccine creator Oxford / AstraZeneca
• Argentina approves Russian single-dose Sputnik Light vaccine
• Omicron: How can scientists update coronavirus vaccines for the new variant?
• against coronavirus for the new variant?
• The ‘déjà vu’ of trans fats, by Elmer Huerta

Follow us on twitter:

!function(d,s,id){var js,fjs=d.getElementsByTagName(s)[0],p=/^http:/.test(d.location)?’http’:’https’;if(!d.getElementById(id)){js=d.createElement(s);js.id=id;js.src=p+’://platform.twitter.com/widgets.js’;fjs.parentNode.insertBefore(js,fjs);}}(document, ‘script’, ‘twitter-wjs’);

.

Deshawn